BIOTECTID: European Patent Office decided to grant a patent for in-vivo diagnostic EP1645
BIOTECTID GmbH announced that the European Patent Office has decided to grant a European patent for the new diagnostic EP1645 used in the in vivo analysis of distribution patterns of human CD4 presenting cell populations.
"This means the achievement of another important milestone in the history of BIOTECTID GmbH ", the CEO of the company, Dr. Ullrich Pigla, said. "This European patent enables Biotectid to plan on a long-term basis and to advance the clinical trials and the market entry for our portfolio products steadily. The Patent Office already told us that during the time for filing an appeal no oppositions to the patent were made. Now we have valid national rights in more than 20 member states of the European patent treaty."
EP 1645 is a fragment of a monoclonal antibody which binds selectively to the CD4 molecule on the surface of specific inflammatory cells. One of the areas of indication is the control and optimization of the use of biopharmaceuticals in the treatment of rheumatoid arthritis.
In addition, a further clinical trial performed ex vivo reveals other very interesting opportunities for the imaging localization of high-risk arteriosclerosis plaques (HRP's). "We expect further clinical results already in 2009; we are sure that we have a very promising new indication line here", Pigla completed.
Other news from the department research and development
